Category Archives: Biotechnology

Agenus Inc (AGEN) is around the top of the Biotechnology industry according to InvestorsObserver. AGEN received an overall rating of 56, which means that it scores higher than 56 percent of all stocks. Agenus Inc also achieved a score of 92 in the Biotechnology industry, putting it above 92 percent of Biotechnology stocks. Biotechnology is ranked 113 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Agenus Inc (AGEN) stock has gained 5.22% while the S&P 500 is down -1.14% as of 11:45 AM on Wednesday, May 19. AGEN is up $0.21 from the previous closing price of $3.93 on volume of 8,516,212 shares. Over the past year the S&P 500 has risen 39.61% while AGEN is up 66.94%. AGEN lost -$1.02 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Agenus Inc (AGEN) Stock.

Read more from the original source:
Is Agenus Inc (AGEN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. Puma will present three posters with audio recordings, the corresponding abstracts of which are now live on the 2021 ASCO Annual Meeting website. The full posters will be available on the Puma and ASCO websites at approximately 9:00 a.m. EDT on June 4, 2021.

Poster Session: Breast CancerLocal/Regional/Adjuvant

Poster Session: Lung CancerNon-Small Cell Metastatic

The abstracts are available online at: asco.org/abstracts

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Visit link:
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting - Business Wire

Sarepta Therapeutics Inc (SRPT) is around the bottom of the Biotechnology industry according to InvestorsObserver. SRPT received an overall rating of 29, which means that it scores higher than 29 percent of all stocks. Sarepta Therapeutics Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 113 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Sarepta Therapeutics Inc (SRPT) stock is trading at $76.05 as of 1:21 PM on Wednesday, May 19, a decline of -$5.39, or -6.62% from the previous closing price of $81.44. The stock has traded between $75.14 and $79.25 so far today. Volume today is 958,142 compared to average volume of 1,130,666.

Click Here to get the full Stock Score Report on Sarepta Therapeutics Inc (SRPT) Stock.

Original post:
Is Sarepta Therapeutics Inc (SRPT) a Smart Choice in Biotechnology Wednesday? - InvestorsObserver

Onconova Therapeutics Inc (ONTX) is near the top in its industry group according to InvestorsObserver. ONTX gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Onconova Therapeutics Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 110 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 73 means the stock is more attractive than 73 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Onconova Therapeutics Inc (ONTX) stock has fallen -11.01% while the S&P 500 has gained 1.05% as of 1:08 PM on Thursday, May 20. ONTX has fallen -$0.10 from the previous closing price of $0.93 on volume of 59,500,813 shares. Over the past year the S&P 500 has gained 39.95% while ONTX has gained 115.79%. ONTX lost -$0.14 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Onconova Therapeutics Inc (ONTX) Stock.

More here:
Is Onconova Therapeutics Inc (ONTX) a Bad Choice in Biotechnology Thursday? - InvestorsObserver

Alkermes Plc (ALKS) is around the middle of the Biotechnology industry according to InvestorsObserver. ALKS received an overall rating of 40, which means that it scores higher than 40 percent of all stocks. Alkermes Plc also achieved a score of 63 in the Biotechnology industry, putting it above 63 percent of Biotechnology stocks. Biotechnology is ranked 113 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 40 would rank higher than 40 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Alkermes Plc (ALKS) stock is higher by 2.12% while the S&P 500 has fallen -0.05% as of 1:17 PM on Friday, May 21. ALKS is higher by $0.47 from the previous closing price of $21.92 on volume of 5,608,985 shares. Over the past year the S&P 500 is higher by 40.98% while ALKS is higher by 35.04%. ALKS lost -$0.59 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Alkermes Plc (ALKS) Stock.

See the original post:
Where Does Alkermes Plc (ALKS) Stock Fall in the Biotechnology Field After It Is Higher By 0.58% This Week? - InvestorsObserver

You may have heard of the Biden Administration's recent proposal to waive the patents for Covid-19 vaccines in order to speed up production and global distribution. In this blog we wanted to discuss why we think this is a mistake and why patent protection is fundamental to the solution and to innovation.

Covid-19 should probably be seen as an extraordinary event and therefore making decisions based purely on the circumstances of COVID-19 that could have ramifications for the whole pharmaceutical and biotechnology sector going forward can have potential adverse consequences.

Viruses do not respect borders, or wealth, and it is tragic that less developed nations sadly do not get access to the best medical advances in the way the more developed world does. One approach to even out this imbalance is to sell a drug or vaccine on a 'not for profit' basis. This is where the pharmaceutical company manufactures the product and charges less wealthy nations only for the cost of production. This is not a new phenomenon; we have seen this happen previously with HIV and Hepatitis C (HCV) drugs. This not only allows global access to vital medicines but also maintains the motivation at a company level to keep innovating, as profits can still be made in countries which can afford to pay the normal price for their products. We should also remind investors of the honourable decision that AstraZeneca took to sell its Covid-19 vaccine on a 'not for profit' basis even to wealthy countries, which is a decision that should be commended for a company whose goal is to generate profits for shareholders. Sadly, the negative press that AstraZeneca has endured since then may have reduced its appetite (and that of its competitors) for this kind of arrangement in the future.

The need for patent protection

Effective and sustained patent protection is an essential element of the pharmaceutical industry's ability to recoup development and production costs from the revenues generated from marketed products. The cost of successfully bringing a new drug to market has steadily increased and protecting the drug's exclusivity, via patents and other methods, generates revenues in the absence of competition for a fixed period of time. After a fixed period, the drug is then generically available at a fraction of the price to society in perpetuity. These companies also invest a significant portion of those profits back into R&D as they are motivated to find a new innovative product to offset the loss of the old now genericised drug. This model is tried and tested globally and underpins the whole sector. It is particularly important as without it, why would companies spend time and money looking for cures to meet unmet medical need, especially for conditions where patient numbers are relatively few?

Patent basics

Patents have a long history, with the English Crown granting patents in the mid-15th century. A patent in the biotech sector is the granting of exclusive rights, a monopoly, by the state for a fixed period of time in exchange for the public disclosure of certain details of an invention at the end of the patent life. The invention may be a device, method of development or production, process or composition of matter, which is new, inventive and useful or industrially applicable. The term of a therapeutic patent is usually 20 years from the filing date, with a potential extension in specific circumstances of 5 years, and this is the case in Europe, the US and Japan. Bearing in mind that it can be 10 to 15 years from filing to the date it is approved for sale, the period during which the company can recoup the developmental costs is limited and, often less than 10 years.

For a patent to be granted, it must demonstrate novelty, utility, and be non-obvious to a skilled person in the trade. For patents relating to therapeutics, the utility is quite easy to demonstrate, while novelty and non-obviousness may be less clear. Any disclosure of the invention prior to filing a patent application may have detrimental future value as the novelty claim is then compromised. This is not uncommon when scientists, eager to publish novel findings, undermine the value of their own inventions.

What does pharma and biotech patent

When dealing with therapeutics, we tend to have major classes of patentable inventions that

relate to pharmaceuticals, although many patents encompass claims that cover most or

all of these to varying degree.

Composition of matter: Product patents form the mainstay of protection for pharmaceutical companies since they claim a novel chemical entity (NCE) or novel biological entity (NBE) and are considered to hold the best protection as they protect the 'core' invention. Patents for a novel chemical/biological entity are generally filed early in the R&D process so usually also have the shortest patent time and expire before other patents in the family of patents that are developed around a significant product.

Formulation: Formulation patents tend to be filed later in the development cycle, or even when the

drug is marketed and provide coverage of innovative delivery forms for purposes of targeted delivery, extended release and other features that improves the characteristics of the original product. At the same time these patents prohibit any generic company from using the same technology making outright generic substitution more difficult. Even if other patents eg composition of matter, have already expired

Process: these patents describe novel methods of producing therapeutic substances and/or formulations. Previously this category was considered of lower value and relatively easy to circumvent. With the recent development of cell therapies that deal with complexities and heterogenicity when growing, modifying and expanding human cells, process patents have become essential.

Use: these protect the use of a drug for treating a given condition or conditions. They may relate to either the original and established use of a drug or to novel (and unanticipated) uses. In many cases 'old' compounds are no longer under patent because of the time lapsed or due to a successful novelty claim deeming the compounds unpatentable. However, if one finds an unanticipated use for the product, a use patent can be granted and may be as solid as a composition of matter in their specific therapeutic use.

Regulatory protection

In some instances when patents are impossible to enforce or relate to a compound that is very old or widely known, the regulatory agencies have introduced incentives for pharmaceutical developers not to discard promising and potential future drugs, just because patents no longer are applicable.

In US, there is a general five year automatic data protection for any drug approved that applies without any patents whatsoever. Once that is lifted, potential generics may start to copy, a process that tends to take 1-3 years, which in reality provides the originator a seven year market protection. Europe has an even better regulatory protection, offering an eight year data protection, an additional two years market entry hiatus which could be extended by another year (8+2+1) if the product expands its use in additional diseases.

Orphan protection

For rare/orphan diseases, the regulatory agencies have added additional incentives for companies to be able to recoup costs incurred when developing drugs for these conditions, as they recognise that the lower number of patients may otherwise deter companies from investing in innovation in these areas. Below is a description of the terms applied:

Table 1: Legislation in major markets offering commercial incentives for orphan drug development

United States

Europe

Japan

Legislation date

1983

2000

1993

Maximum prevalence criteria

7.5/10,000 people

5/10,000 people

4/10,000 people

Market exclusivity

7 years

10 years

10 years

Fee waiver

Yes

At least partial

No

Source: Frost & Sullivan

We at IBT are always scrutinizing a potential investment prospects IP protection as the basis of our investment decision. Lack of effective IP protection may render a company uninvestable, in our view, and this is core to our thesis. We are seeing new variants of Covid-19 appearing which is a worrying yet predictable result of a pandemic. Removing patent protection may deter the vaccine companies from continuing their work in finding future new vaccines to fight the moving target that is Covid-19. Angela Merkel's comments following the Biden announcement said that such a move would have 'severe complications' for the sector. Although IBT does not currently invest in vaccine companies, we also view this proposal as a deeply concerning for the remainder of the biotech sector.

Disclaimer

International Biotechnology Trust plc published this content on 21 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2021 06:16:02 UTC.

Read the original:
International Biotechnology Trust : Innovation is the key not the culprit IP waiving is counterproductive - Marketscreener.com

A rating of 87 puts Intra-Cellular Therapies Inc (ITCI) near the top of the Biotechnology industry according to InvestorsObserver. Intra-Cellular Therapies Inc's score of 87 means it scores higher than 87% of stocks in the industry. Intra-Cellular Therapies Inc also received an overall rating of 52, putting it above 52% of all stocks. Biotechnology is ranked 110 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Intra-Cellular Therapies Inc (ITCI) stock is trading at $39.13 as of 2:16 PM on Thursday, May 20, an increase of $1.05, or 2.76% from the previous closing price of $38.08. The stock has traded between $37.89 and $39.50 so far today. Volume today is less active than usual. So far 352,890 shares have traded compared to average volume of 507,343 shares.

Click Here to get the full Stock Score Report on Intra-Cellular Therapies Inc (ITCI) Stock.

More:
Should Biotechnology Stock Intra-Cellular Therapies Inc (ITCI) Be in Your Portfolio Thursday? - InvestorsObserver

Get Sample Report Buy Complete Report

2-Chlorocinnamic Acid Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

2-Chlorocinnamic Acid Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=34509

Top Key Players Profiled in this report are:

EMMX Biotechnology LLC, Matrix Scientific, Alfa Aesar, Apollo Scientific Ltd, Sigma-Aldrich, J&K Scientific.

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global 2-Chlorocinnamic Acid market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the 2-Chlorocinnamic Acid market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the 2-Chlorocinnamic Acid market.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=34509

The cost analysis of the Global 2-Chlorocinnamic Acid Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report:

Table of Contents

Global 2-Chlorocinnamic Acid Market Research Report 2021

Chapter 1 2-Chlorocinnamic Acid Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global 2-Chlorocinnamic Acid Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=34509

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

View post:
2-Chlorocinnamic Acid Market to Witness Robust Expansion by 2027 | EMMX Biotechnology LLC, Matrix Scientific, Alfa Aesar Brockville Observer -...

Biotechnology Based Chemical Market report is a sorted analysis of the local and global market that wills details information and data about the market in its current context. This report has been put together by The Research Insights to enable businesses optimize on their ROI (Return on investment).

This report Biotechnology Based Chemical Market has look into critical parameters that drives a business like the market in totality, the economy related factors like policies, revenue generation scope for a market segment, resourcing costs and many more.

the globalbio-based chemicals market was valued at $xx billion in 2020. Moreover, it is expected to reach $32.04 billion by 2025, growing with a CAGR of 15.01% during the forecast period.

Ask for a sample copy:

https://www.theresearchinsights.com/request_sample.php?id=103844&mode=93

The report presents the market competitive landscape and corresponding detailed analysis of the major vendor/key players in the market.

Top Companies:- in the Global Biotechnology Based Chemical Market: Queensland?s world-class agriculture industry, Sarnia-Lambton Research, UK and Norway business funding agencies, Technology Strategy Board (TSB), Innovation Norway, other.

Global Biotechnology Based Chemical Market Split by Product Type and Applications

This report segments the Biotechnology Based Chemical Market on the basis of Types are:-

by Types

Bio-pharma

Agri-biotech

Bio-informatics and

Bio-services

Others

On the basis of Application, the Biotechnology Based Chemical Market segmented into:-

Food and beverages

Agriculture

Fuel

Energy

Animal feed

Pharmaceuticals and nutrition

Paper and pulp

Cosmetics and toiletries

Plastics and fibres

Others

Regional outlook: The regions covered in the reports of the Biotechnology Based Chemical Market are

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Get a discount on this report

https://www.theresearchinsights.com/ask_for_discount.php?id=103844&mode=93

How will this report be worth your money?

-By giving a comprehensive insight into the markets

-Competition study and analysis

-Will help in gaining a different perspective to approach a crisis when needed

-Data driven statistics that will help in tracing growth of the market segment or the product category

-A global analysis that will give the reader a broader perspective to do a SWOT analysis

-Presents case contextual studies from the past and the current scenarios as well

-Experts word of advice.

What are the market factors that are explained in the report?

Biotechnology Based Chemical Market is a data intensive report that includes analysis by experts to help in drawing conclusions. It will also be an aid in formulating strategies for an existing or a new business. One of the most read topics that will interest the readers is the information and the analysis of the competitive market.

If You Have Any Query, Ask Our Experts:

https://www.theresearchinsights.com/enquiry_before_buying.php?id=103844&mode=93

If you are planning to invest into new products or trying to understand this growing Market this report is your starting point.

About us:

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:

Robin

-Sales manager

-Contact number: +91-996-067-0000

sales@theresearchinsights.com

http://www.theresearchinsights.com

Continue reading here:
Biotechnology Based Chemical Market Advancements, Rising Trends and Growth Forecast 2020 to 2025 The Courier - The Courier

Akero Therapeutics Inc (AKRO) is near the top in its industry group according to InvestorsObserver. AKRO gets an overall rating of 48. That means it scores higher than 48 percent of stocks. Akero Therapeutics Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 113 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 48 means the stock is more attractive than 48 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Akero Therapeutics Inc (AKRO) stock is lower by -4.29% while the S&P 500 has gained 0.34% as of 10:43 AM on Friday, May 21. AKRO has fallen -$1.21 from the previous closing price of $28.23 on volume of 48,271 shares. Over the past year the S&P 500 is higher by 41.53% while AKRO has gained 15.32%. AKRO lost -$2.49 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Akero Therapeutics Inc (AKRO) Stock.

View original post here:
Is Akero Therapeutics Inc (AKRO) a Smart Choice in Biotechnology Friday? - InvestorsObserver